Replace four pm EDT: The board of consultants monitoring the medical trial of AstraZeneca’s COVID-19 vaccine decided that the vaccine is definitely between 69 % and 74 % efficient at stopping symptomatic illness—not 79 % efficient, as AstraZeneca introduced Monday.
Based on a report by The Washington Put up, the trial’s Knowledge and Security Monitoring Board (DSMB) had been in conferences with the corporate by way of February and March and noticed information that indicated the 69-to-74 % efficacy vary. The board “strongly advisable” that the newest data be included within the firm’s Monday press launch.
Nonetheless, the press launch Monday solely acknowledged an efficacy of 79 % and, in a second press launch Tuesday, the corporate famous that that they had used an information cut-off of February 17.
Learn 10 remaining paragraphs | Feedback